BMO Capital analyst Joanne Wuensch raised her price target on DexCom to $190 after holding talks with its management, saying the company is looking to sustain its growth by expanding its offerings to treat the 4M gestational, 14M hospital, 27M Type 2 non-intensive, and 84M pre-diabetes patients. The analyst contends that Dexco has the momentum in place for several years, though its immediate task is doubling its manufacturing capacity for G6 CGM by the end of 2019, followed by the FDA approval of its G7 CGM by the end of 2020. Wuensch keeps her outperform rating on DexCom.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.